Navigation Links
Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that results from nonhuman primate studies of a Vaxfectin(R)-formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising approach to the development of a measles vaccine to address an unmet need for human infants. Vical recently reported breakthrough preliminary Phase 1 trial results for the company's H5N1 pandemic influenza DNA vaccines formulated with the same Vaxfectin(R) adjuvant.

In the article, authors from the Johns Hopkins Bloomberg School of Public Health, the Johns Hopkins School of Medicine, and Vical detailed results from studies in juvenile and infant nonhuman primates demonstrating that the vaccine induced rapid, durable, high-avidity, neutralizing antibody responses; measles-specific memory T-cells; and long-term protection against measles challenge. The article concluded, "A Vaxfectin(R)-formulated DNA vaccine is a promising approach for the development of a new measles vaccine for young children." The ability to induce broad-based and lasting immune responses, confirmed by long-term protection, adds further evidence supporting the potential for Vaxfectin(R)-formulated DNA vaccines.

The measles studies were conducted in collaboration with Diane E. Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation. "Although a safe and effective live attenuated commercial measles vaccine is available, measles continues to be a major cause of infant mortality," said Dr. Griffin. "The immaturity of the immune syst
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... have made great strides in saving China,s endangered national ... over 65 giant panda reserves that have been established ... just 1596 pandas remain in the wild. , ... save the panda by improving genetic diversity, avoid inbreeding ... how are these high-profile programs doing so far? , ...
(Date:7/23/2014)... LOS ANGELES , July 23, 2014 /PRNewswire-iReach/ -- ... enhance cognitive performance for the long term. They are ... competitive edge of sustained energy as an alternative to ... launch Think Drinks on Indiegogo on July 29, 2014, ... the 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... Last year, Formedix celebrated ... global provider of data management solutions for clinical trials. ... system for electronic data capture (EDC) and clinical data ... study execution tools added TrialMaster to its Transform for ... of Transform for TrialMaster, is being released this week, ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3
... Calif., Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2007 after the market closes on Tuesday, ... at 4:30 p.m. EST,1:30 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... initiated by end of 2007 -, PRAGUE, Czech ... ) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... reduction in new or,enlarged gadolinium-enhancing lesions when daclizumab is ... multiple,sclerosis (MS). These data will be presented tomorrow at ...
... LOWELL, Mass., Oct. 11 More than half ... but,are concerned about the current state and national economies, ... today by the Massachusetts,Economic Assessment and Analysis Project (MEAAP) ... Fifty-four percent of those surveyed said their own ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6Survey Sees Mass. CEOs as Bullish on Own Businesses 2
(Date:7/24/2014)... out of York University shows a surprisingly effective way ... fungus: moose saliva (yes moose saliva). , Published ... inhibits a grassendophyte mutualism" shows that moose and reindeer ... a fungus called epichlo festucae that produces the toxin ... , "Plants have evolved defense mechanisms to protect themselves, ...
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... fire hazard in the United States, wildland managers often ... and suppressed trees (ladder fuels). These cuttings and ... low fire danger in order to dispose of the ... pollutants, managers often cover all or part of the ... as agricultural plastic, in order to keep water out. ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... years of feathers from natural history museums in the ... track increases in the neurotoxin methylmercury in the black-footed ... forages extensively throughout the Pacific. The ... most likely from human-generated emissions, can be observed and ...
... MARC (Minority Access to Research Careers) Program has announced ... Lakes Bioinformatics Conference (GLBIO) to be held at Ohio ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... Oxygenation brings dead sea bottoms to life. This ... ecosystems that enable nature itself to deal with eutrophication. ... researchers at the University of Gothenburg have demonstrated that ... effective. A large wind-driven pump is now to be ...
Cached Biology News:Mercury on the rise in endangered Pacific seabirds 2Oxygenation at a depth of 120 meters can save the Baltic Sea 2
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Fetal Calf Serum Replacement (Bistec) serum...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Biology Products: